ResearcherLanzhou University Second HospitalActive in the last 2 years

Junhong Guan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4900-0610; OpenAlex author ID A5018203024. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 3

Single-cell and spatial transcriptomics uncover a THBS2⁺ CAF-KRT17⁺ malignant cell axis drives progression and immunotherapy resistance in pancreatic cancer. Last author DOI 10.1016/j.tranon.2026.102939 ↗
KRAS G12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. Co-author DOI 10.1016/j.xcrm.2025.101966 ↗
Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress. Co-author DOI 10.1053/j.gastro.2023.02.025 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Rui Ma · 1 shared paper, 2026 · strength 0.33
- Paper Single-cell and spatial transcriptomics uncover a THBS2⁺ CAF-KRT17⁺ malignant cell axis drives progression and immunoth… DOI 10.1016/j.tranon.2026.102939 ↗
Haofei Chen · 1 shared paper, 2026 · strength 0.33
- Paper Single-cell and spatial transcriptomics uncover a THBS2⁺ CAF-KRT17⁺ malignant cell axis drives progression and immunoth… DOI 10.1016/j.tranon.2026.102939 ↗
Weixiong Zhu · 1 shared paper, 2026 · strength 0.33
- Paper Single-cell and spatial transcriptomics uncover a THBS2⁺ CAF-KRT17⁺ malignant cell axis drives progression and immunoth… DOI 10.1016/j.tranon.2026.102939 ↗
Xiangyan Jiang · 2 shared papers, 2023–2025 · strength 0.33
- Paper KRAS G12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for … DOI 10.1016/j.xcrm.2025.101966 ↗
- Paper Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replicati… DOI 10.1053/j.gastro.2023.02.025 ↗
Tao Wang · 2 shared papers, 2023–2025 · strength 0.33
- Paper KRAS G12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for … DOI 10.1016/j.xcrm.2025.101966 ↗
- Paper Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replicati… DOI 10.1053/j.gastro.2023.02.025 ↗
Zeyuan Yu · 2 shared papers, 2023–2025 · strength 0.33
- Paper KRAS G12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for … DOI 10.1016/j.xcrm.2025.101966 ↗
- Paper Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replicati… DOI 10.1053/j.gastro.2023.02.025 ↗
Zuoyi Jiao · 2 shared papers, 2023–2025 · strength 0.33
- Paper KRAS G12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for … DOI 10.1016/j.xcrm.2025.101966 ↗
- Paper Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replicati… DOI 10.1053/j.gastro.2023.02.025 ↗
Yuman Dong · 1 shared paper, 2025 · strength 0.18
- Paper KRAS G12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for … DOI 10.1016/j.xcrm.2025.101966 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.